Lipocine (LPCN)
(Delayed Data from NSDQ)
$4.73 USD
-0.07 (-1.41%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $4.77 +0.04 (0.85%) 7:56 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
LPCN 4.73 -0.07(-1.41%)
Will LPCN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LPCN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for LPCN
Lipocine Initiates New ATM Offering, Ends Previous Agreement
LPCN, ADIL and CADL among pre-market losers
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Lipocine's LPCN 2401 shows positive Phase 2 results in obesity trial